Precursor Condition
Cervical Intraepithelial Neoplasia
CI-CAN-00000664CINExplore in graph →
Precursor45 active trials
Loading cancer entity…
Precursor Condition
CI-CAN-00000664CINExplore in graph →
Clinical trials
316 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06191133 | Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma | recruiting | Phase 1 | 24 | Lindsay Ferguson, MDOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT04131413 | HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia | recruiting | Phase 1 | 48 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT02858310 | E7 TCR T Cells for Human Papillomavirus-Associated Cancers | completed | Phase 1 / Phase 2 | 224 | National Cancer Institute (NCI)NIH | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05502367 | A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia | terminated | Phase 1 / Phase 2 | 44 | Antiva BiosciencesINDUSTRY | 3 | Feb 19, 2026 | clinicaltrials |
| NCT06263582 | Pharmacokinetics of Intravaginal, Self-administered Artesunate Vaginal Pessaries Among Women in Kenya | completed | Phase 1 | 12 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT06137950 | Interferon Alpha Therapy for Cervical CINI and HPV Infection | completed | Phase 1 | 60 | Mongolian National University of Medical SciencesOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT05496231 | A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age | completed | Phase 1 / Phase 2 | 1,080 | GlaxoSmithKlineINDUSTRY | 8 | Feb 3, 2025 | clinicaltrials |
| NCT05362955 | 5-fluorouracil Following Cervical Intraepithelial Neoplasia Treatment Among HIV-positive Women in East Africa | completed | Phase 1 | 12 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT06273553 | A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3 | not yet recruiting | Phase 1 / Phase 2 | 39 | RinuaGene Biotechnology Co., Ltd.INDUSTRY | 0 | Feb 22, 2024 | clinicaltrials |
| NCT02529930 | An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3) | completed | Phase 1 / Phase 2 | 34 | Nykode Therapeutics ASAINDUSTRY | 1 | Jul 13, 2022 | clinicaltrials |
| NCT03321461 | TMTP1-ICG Mapping in Colposcopy-directed Biopsy | unknown | Phase 1 | 40 | Huazhong University of Science and TechnologyOTHER | 1 | Jun 30, 2021 | clinicaltrials |
| NCT02354534 | Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3) | completed | Phase 1 | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT03697226 | Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection. | completed | Phase 1 | 8 | Antiva BiosciencesINDUSTRY | 1 | Jan 13, 2021 | clinicaltrials |
| NCT04411134 | E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 15, 2020 | clinicaltrials |
| NCT03676101 | Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | completed | Phase 1 | 90 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03239223 | Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection | completed | Phase 1 | 16 | Antiva BiosciencesINDUSTRY | 2 | Jul 10, 2019 | clinicaltrials |
| NCT03870113 | DC Vaccines Targeting HPV16/18 E6/E7 Protein to Regress CINI/CIN2 | unknown | Phase 1 | 80 | Shenzhen People's HospitalOTHER | 1 | Mar 14, 2019 | clinicaltrials |
| NCT00988559 | Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3) | completed | Phase 1 | 132 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 9, 2018 | clinicaltrials |
| NCT03141463 | Vvax001 Cancer Vaccine in (Pre) Malignant Cervical Lesions | completed | Phase 1 | 12 | University Medical Center GroningenOTHER | 1 | May 3, 2018 | clinicaltrials |
| NCT02195089 | Efficacy and Safety Study of BLS_ILB_E710c for the Fertile Women With Cervical Intraepithelial Neoplasia(CIN3) | completed | Phase 1 / Phase 2 | 19 | BioLeaders CorporationINDUSTRY | 1 | Apr 19, 2016 | clinicaltrials |
| NCT00154089 | A Pilot Study of EM-1421 for the Treatment of Cervical Intraepithelial Neoplasia | completed | Phase 1 / Phase 2 | 8 | Erimos PharmaceuticalsINDUSTRY | 1 | Feb 23, 2016 | clinicaltrials |
| NCT01338051 | The Development of a "Mother/Child, Screen, Treat and Vaccinate Program" in Manchay and Iquitos, Peru(PERCAPS) | completed | Phase 1 | 642 | Preventive Oncology International, Inc.OTHER | 1 | Apr 21, 2014 | clinicaltrials |
| NCT01035580 | Trial on Safety and Pharmacokinetics of Intravaginal Curcumin | completed | Phase 1 | 13 | Emory UniversityOTHER | 1 | Nov 28, 2013 | clinicaltrials |
| NCT01880411 | Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity PEK Fusion Protein Vaccine | unknown | Phase 1 | 15 | HealthBanks Biotech Co., Ltd.INDUSTRY | 0 | Jun 19, 2013 | clinicaltrials |
| NCT00369018 | A Dose-finding Study of MAL and HAL Photodynamic Therapy of Cervical Premalignant Lesions. | completed | Phase 1 / Phase 2 | 96 | PhotocureINDUSTRY | 2 | Nov 30, 2010 | clinicaltrials |
| NCT00989443 | Safety and Tolerability of Cidofovir Gel Applied on Cervix Squamous Lesions | completed | Phase 1 | 6 | Mithra PharmaceuticalsINDUSTRY | 1 | Oct 21, 2010 | clinicaltrials |
| NCT00493545 | Safety Study to Test the Safety of HspE7 and Poly-ICLC Given in Patients With Cervical Intraepithelial Neoplasia | unknown | Phase 1 | 24 | Nventa Biopharmaceuticals CorporationINDUSTRY | 1 | May 7, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Jul 27, 2026source: clinicaltrials